Skip to Search
Skip to Navigation
Skip to Main Content
Skip to Footer
About Us
Life Sciences Publications
Our Medicines
Topic Articles
Topic Discussions
Login
Google Translate
Select language
English
French
Spanish
Login
Username
*
Password
*
Staff Login
×
Google Translate
Select language
English
French
Spanish
Login
Menu
Site Search
Search Options
Resources
Everything
Advanced Search
Uptodate
All
Title Search
Author
Patients & Caregivers
Healthcare Providers
Researchers & Partners
Investors
menu
About Us
Life Sciences Publications
Our Medicines
Topic Articles
Topic Discussions
Google News
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Sage Therapeutics (NASDAQ:SAGE) Reaches New 12-Month Low After Analyst Downgrade - Defense World
Sage Therapeutics: Tremors Of Trouble, But PPD Progress (Rating Downgrade) (NASDAQ:SAGE) - Seeking Alpha
Sage Therapeutics: Tremors Of Trouble, But PPD Progress (Rating Downgrade) (NASDAQ:SAGE) - Seeking Alpha
Sage Therapeutics (NASDAQ:SAGE) Price Target Lowered to $17.00 at Scotiabank - MarketBeat
Sage Therapeutics (NASDAQ:SAGE) Price Target Cut to $17.00 - MarketBeat
Sage Therapeutics (NASDAQ:SAGE) Stock Rating Lowered by JPMorgan Chase & Co. - MarketBeat
Sage Therapeutics (NASDAQ:SAGE) Stock Rating Lowered by JPMorgan Chase & Co. - MarketBeat
Sage Therapeutics (NASDAQ:SAGE) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
Sage Therapeutics (NASDAQ:SAGE) Rating Reiterated by HC Wainwright - MarketBeat
Sage Therapeutics (NASDAQ:SAGE) Rating Reiterated by HC Wainwright - MarketBeat
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
next ›
last »
×